Pathogenic Th17 cell-mediated liver fibrosis contributes to resistance to PD-L1 antibody immunotherapy in hepatocellular carcinoma

• DOI: 10.1016/j.intimp.2024.111601
• Publication Date: 2024-02-13T01:34:11Z
• Authors: Meiying Song; Luoyang Wang; Suli Jiang; Jie Liang; Wei Li; Wei Rao; Qiaochu Du; Guixian Liu; Haining Meng; Lei Tang; Zhifei Li; Yanyan Yang; Li Zhang; Bei Zhang
• Keywords: Immune checkpoint; Combination therapy; Liver Cancer; Targeted Therapy

Understanding the mechanisms of resistance of hepatocellular carcinoma (HCC) to targeted therapies and immune checkpoint blockade is critical for the development of new combination therapies and improving patient survival. Here, we found that in HCC, anti-programmed cell death 1 ligand 1 (PD-L1) therapy reduces liver cancer growth, but the tumors eventually become resistant to continued therapy. Experimental analyses shows that the infiltration of pathogenic T helper 17 (pTh17) cells increases in drug-resistant HCC, and pTh17 cells secrete interleukin-17A (IL-17A), which promotes the expression of PD-L1 on the surface of HCC cells and produces resistance to anti-PD-L1 therapy. Anti-IL-17A combined with PD-L1 blockade significantly increased the infiltration of cytotoxic CD8+ T cells expressing high levels of interferon-γ and reduced treatment resistance in HCC. These results support the combination of anti-PD-L1 and anti-IL-17A as a novel strategy to induce effective T cell-mediated anti-tumor immune responses.